I need an answer to a question fast -

If someone like Dr. Janet Woodcock at OWS were to ask to see the data from the CD12 Interim Review, could she get it? Isn't that up to the trial sponsor, Cytodyn?

I don't see the need to unblind the data for Cytodyn or us shareholders or many others if the data can be unblinded on request by individuals at ACTIV or CDER or CTAP or someone like that. Getting the data to them is the important thing.

I'm trying to crowbar my way into the HHS bureaucracy. Any seasoned bureaucracy crackers can help.

First, help on the unblinding question.

Thanks.